IP Library Granted Patent US 10,106,623
Granted Patent B2
US 10,106,623 · App. 15/118,767 · Granted Oct 23, 2018

Bispecific antibodies for use in stem cell transplantation

Inventors: Michael Uhlin (Falun, SE); Jonas Mattsson (Tullinge, SE)
C07K16/468A61K39/39558A61K45/06C07K16/2803C07K16/2896A61K2039/505C07K2317/31C07K2317/52C07K2317/565C07K2317/567C07K2317/622C07K2317/73
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,106,623
App. No.
15/118,767
Granted
Oct 23, 2018
Kind
B2
Abstract

New monoclonal antibodies for use in pre-treatments prior to stem cell transplantations are disclosed. The antibodies may be used to kill malignant cells and/or stem cells prior to stem cell transplantation. The antibodies can be used for treating hematologic diseases and hematological malignancies, such as leukemia and MDS. The antibodies of the invention might be multi- or bi-specific, such as BiTEs.

Claims (19)

1. A therapeutic agent comprising

the amino acid sequence:

SEQ ID NO: 63

QIQLVQSGSELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLKWMGW

INTNTGEPKYAEEFKGRFALSLDTSVSTAYLQINSLKAEDTAVYFCARGY

GNYARGAWLAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCL

VKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGT

QTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP

KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ

YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE

PQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTP

PVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSP

GKGGGGSGGGGSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYT

MHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQL

SSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGS

GGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRW

IYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLT

FGAGTKLELK.

2. A pharmaceutical composition comprising the therapeutic agent according to claim 1 and a pharmaceutically-acceptable diluent, carrier or excipient.

Continuity (2)
Provisional Application 61938791 · Feb 12, 2014
Related Publication 20170298148A1 · Oct 19, 2017
Cited By (3)
US 12,428,493 US 12,565,529 US 12,655,218